Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.

Literature DB >> 32133105

Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.

Mingjing Li¹, Zhaoyu Wang¹, Bocheng Yan¹, Xiaona Yin¹, Yue Zhao¹, Fan Yu², Meng Meng¹, Yonghui Liu¹, Wei Zhao¹.

Abstract

MUC1 is an attractive target for cancer vaccines as a result of its over-expression and aberrant glycosylation pattern on many tumor cells. However, the low immunogenicity of MUC1 and immune tolerance have limited its application. Herein, we designed MUC1-based tricomponent antitumor vaccines adjuvanted with fibroblast stimulating lipopeptide 1 (FSL-1). Immunological results indicate that the glycosylated tricomponent vaccine candidate has elicited both humoral and cellular immune responses. The induced antibodies could effectively bind to MCF-7. Furthermore, the vaccine exhibited an obvious reduction in tumour burden. This journal is © The Royal Society of Chemistry 2019.

Entities: CellLine Disease Gene

Year: 2019 PMID： 32133105 PMCID： PMC6991171 DOI： 10.1039/c9md00254e

Source DB: PubMed Journal: Medchemcomm ISSN： 2040-2503 Impact factor: 3.597

33 in total

1. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.

Authors: Hui Cai; Zhan-Yi Sun; Zhi-Hua Huang; Lei Shi; Yu-Fen Zhao; Horst Kunz; Yan-Mei Li
Journal: Chemistry Date: 2012-12-23 Impact factor: 5.236

2. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.

Authors: Yonghui Liu; Wenpeng Zhang; Qianqian He; Fan Yu; Tianbang Song; Tingting Liu; Zhenqing Zhang; Jun Zhou; Peng George Wang; Wei Zhao
Journal: Chem Commun (Camb) Date: 2016-08-17 Impact factor: 6.222

3. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.

Authors: Natascha Stergiou; Nikola Gaidzik; Anne-Sophie Heimes; Sarah Dietzen; Pol Besenius; Jörg Jäkel; Walburgis Brenner; Marcus Schmidt; Horst Kunz; Edgar Schmitt
Journal: Cancer Immunol Res Date: 2018-11-09 Impact factor: 11.151

4. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.

Authors: Zhaojun Yin; Xuanjun Wu; Katarzyna Kaczanowska; Suttipun Sungsuwan; Marta Comellas Aragones; Christian Pett; Jin Yu; Claire Baniel; Ulrika Westerlind; M G Finn; Xuefei Huang
Journal: ACS Chem Biol Date: 2018-05-30 Impact factor: 5.100

5. From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix.

Authors:
Journal: Angew Chem Int Ed Engl Date: 2000-03 Impact factor: 15.336

6. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

Authors: Vani Lakshminarayanan; Pamela Thompson; Margreet A Wolfert; Therese Buskas; Judy M Bradley; Latha B Pathangey; Cathy S Madsen; Peter A Cohen; Sandra J Gendler; Geert-Jan Boons
Journal: Proc Natl Acad Sci U S A Date: 2011-12-14 Impact factor: 11.205

7. Robust immune responses elicited by a fully synthetic three-component vaccine.

Authors: Sampat Ingale; Margreet A Wolfert; Jidnyasa Gaekwad; Therese Buskas; Geert-Jan Boons
Journal: Nat Chem Biol Date: 2007-09-02 Impact factor: 15.040

8. Syntheses and Immunological Evaluation of Self-Adjuvanting Clustered N-Acetyl and N-Propionyl Sialyl-Tn Combined with a T-helper Cell Epitope as Antitumor Vaccine Candidates.

Authors: Tsung-Che Chang; Yoshiyuki Manabe; Yukari Fujimoto; Shino Ohshima; Yoshie Kametani; Kazuya Kabayama; Yuka Nimura; Chun-Cheng Lin; Koichi Fukase
Journal: Angew Chem Int Ed Engl Date: 2018-06-07 Impact factor: 15.336

Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.

1. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.

2. Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.

3. Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.

4. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.

5. From the Laboratory to the Clinic: A Retrospective on Fully Synthetic Carbohydrate-Based Anticancer Vaccines Frequently used abbreviations are listed in the appendix.

6. Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine.

7. Robust immune responses elicited by a fully synthetic three-component vaccine.

8. Syntheses and Immunological Evaluation of Self-Adjuvanting Clustered N-Acetyl and N-Propionyl Sialyl-Tn Combined with a T-helper Cell Epitope as Antitumor Vaccine Candidates.

9. Water-soluble polymers coupled with glycopeptide antigens and T-cell epitopes as potential antitumor vaccines.

10. A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.

Review 1. Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.

Review 2. Mucins as anti-cancer targets: perspectives of the glycobiologist.

3. Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.

Review 4. Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy.